A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

NCT00872014 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma
Inoperable Hepatocellular Carcinoma

Interventions

DRUG: AMG 386
DRUG: AMG 386
DRUG: Sorafenib

Sponsor

Amgen